News Focus
News Focus
Followers 142
Posts 23872
Boards Moderated 0
Alias Born 06/13/2011

Re: HDGabor post# 89530

Saturday, 08/20/2016 1:49:27 PM

Saturday, August 20, 2016 1:49:27 PM

Post# of 447398
Gabor ...an example of the criticism of I-IT trial

Randall Mark Zusman, MD: "The guidelines, although also controversial, really focus on supporting the clinical trials conducted to date that have emphasized the use of maximal lipid-lowering therapies. And this trial doesn't really address that question, because it's a study of submaximal statin therapy versus submaximal statin therapy with an augmented cholesterol-lowering drug.

I think that my major concern or criticism of this study was it wasn't maximal statin therapy versus maximal statin therapy plus ezetimibe.

Given that the guidelines currently recommend maximal statin dosages or maximum lipid-lowering dosages, they're not talking about 40 mg of simvastatin, a modest dose of a modestly effective statin.

This study emphasizes the importance of lowering LDL cholesterol further than modest cholesterol lowering therapies, but doesn't address the question that has been reviewed and recommendations from the AHA/ACC panel."


-------------------------
With your powers of DD I'm sure you can find more ...smile

JELIS was sub optimal use of Statins
R-IT will be optimal use of Statins ...often with max dose of the highest intensity Statins

Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News